论文部分内容阅读
目的:对比分析顺铂不同给药途径联合紫杉醇治疗晚期卵巢癌的疗效。方法:选取2014年9月~2016年9月我院收治的晚期卵巢癌患者80例,随机分为观察组与对照组,各40例,观察组采用腹腔灌注顺铂联合紫杉醇治疗,对照组采用静脉滴注顺铂联合紫杉醇治疗。结果:观察组卵巢癌晚期治疗有效率(77.5%)显著高于对照组(57.5%)(P<0.05)。在不良反应方面,除骨髓抑制外,观察组胃肠道反应、肝肾毒性、神经毒性和肌肉关节痛发生率显著高于对照组(P<0.05)。结论:采用腹腔灌注顺铂联合紫杉醇治疗晚期卵巢癌疗效较静脉滴注顺铂联合紫杉醇疗效更好,且患者对不良反应耐受性较好,值得进一步研究和推广。
OBJECTIVE: To compare and analyze the efficacy of different routes of cisplatin combined with paclitaxel in the treatment of advanced ovarian cancer. Methods: From September 2014 to September 2016, 80 patients with advanced ovarian cancer admitted to our hospital were randomly divided into observation group and control group, 40 cases in each. The observation group was treated with intraperitoneal cisplatin plus paclitaxel. The control group Intravenous cisplatin combined with paclitaxel treatment. Results: The effective rate of advanced ovarian cancer treatment in observation group (77.5%) was significantly higher than that in control group (57.5%) (P <0.05). Adverse reactions, in addition to bone marrow suppression, the observation group gastrointestinal reactions, liver and kidney toxicity, neurotoxicity and muscle joint pain incidence was significantly higher than the control group (P <0.05). Conclusion: The efficacy of cisplatin plus paclitaxel in the treatment of advanced ovarian cancer is better than that of intravenous cisplatin and paclitaxel, and the patients are well tolerated with adverse reactions. It is worth further study and promotion.